View of CRISPR-Cas9 in Myelodysplastic Syndromes: The Potential of Editing DNMT3A, TET2, ASXL1, TP53, and SF3B1 to Prevent Disease Progression—A Literature Review

Return to Article Details CRISPR-Cas9 in Myelodysplastic Syndromes: The Potential of Editing DNMT3A, TET2, ASXL1, TP53, and SF3B1 to Prevent Disease Progression—A Literature Review Download Download PDF